Equities

Spyre Therapeutics Inc

Spyre Therapeutics Inc

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3395693
Total Receivables, Net00.380.82
Total Inventory------
Prepaid expenses2.256.174.95
Other current assets, total------
Total current assets3426299
Property, plant & equipment, net07.259.15
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.010.090.04
Total assets34271110
LIABILITIES
Accounts payable170.683.32
Accrued expenses131314
Notes payable/short-term debt000
Current portion long-term debt/capital leases--0.020.42
Other current liabilities, total1.390.522.36
Total current liabilities321520
Total long term debt000.02
Total debt00.020.43
Deferred income tax------
Minority interest------
Other liabilities, total416.185.83
Total liabilities732126
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital763476426
Retained earnings (accumulated deficit)(764)(426)(342)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.30(0.05)(0.02)
Total equity2695084
Total liabilities & shareholders' equity34271110
Total common shares outstanding362.611.97
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.